0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

CLINICAL SYNTHESIS   |    
Novel Developments in the Pharmacological Management of Insomnia
David N. Neubauer, M.D.
FOCUS 2014;12:38-44. doi:10.1176/appi.focus.12.1.38
View Author and Article Information

Author Information and CME Disclosure

David N. Neubauer, M.D., Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

Dr. Neubauer reports no financial relationships with commercial interests.

Address correspondence to David N. Neubauer, M.D., Johns Hopkins Bayview Medical Center, 4940 Eastern Ave., Box 151, Baltimore, MD 21224; e-mail: neubauer@jhmi.edu

Abstract

A wide range of substances has been used in the attempt to improve sleep. Advances in the basic science of sleep-wake neurophysiology are driving the exploration of new pharmacologic approaches with continued improvement in efficacy and safety. Investigational compounds presently under review with the Food and Drug Administration (FDA) that may be approved for sleep disorder indications include suvorexant and tasimelteon. Safety problems plagued early sedating compounds. The current generation of FDA-approved insomnia medications has been evaluated for safety and efficacy, and detailed prescribing information is available for each drug. FDA-approved medications indicated for the treatment of insomnia include several benzodiazepine receptor agonists (benzodiazepines and nonbenzodiazepines), a single melatonin receptor agonist, and a single histamine H1 receptor antagonist. Novel alternate delivery formulations of zolpidem are now available, the most recent with an indication for use with middle-of-the-night awakenings.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
Table 1.FDA-Approved Insomnia Treatment Medications
Anchor for Jump
Table 2.Indications and Side Effects of FDA-Approved Insomnia Treatment Medications
+

References

Schutte-Rodin  S;  Broch  L;  Buysse  D;  Dorsey  C;  Sateia  M:  Clinical guideline for the evaluation and management of chronic insomnia in adults.  J Clin Sleep Med 2008; 4:487–504
[PubMed]
 
Bateson  AN:  Further potential of the GABA receptor in the treatment of insomnia.  Sleep Med 2006; 7:3–9
[CrossRef]
 
Fuller  PM;  Gooley  JJ;  Saper  CB:  Neurobiology of the sleep-wake cycle: Sleep architecture, circadian regulation, and regulatory feedback.  J Biol Rhythms 2006; 21:482–493
[CrossRef] | [PubMed]
 
Rudolph  U;  Möhler  H:  GABA-based therapeutic approaches: GABAA receptor subtype functions.  Curr Opin Pharmacol 2006; 6:18–23
[CrossRef] | [PubMed]
 
Erman  M;  Guiraud  A;  Joish  VN;  Lerner  D:  Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial.  Sleep 2008; 31:1371–1378
[PubMed]
 
Krystal  AD;  Erman  M;  Zammit  GK;  Soubrane  C;  Roth  T; ZOLONG Study Group:  Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.  Sleep 2008; 31:79–90
[PubMed]
 
Krystal  AD;  Walsh  JK;  Laska  E;  Caron  J;  Amato  DA;  Wessel  TC;  Roth  T:  Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.  Sleep 2003; 26:793–799
[PubMed]
 
U.S. Food and Drug Administration. Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses. January 10, 2013 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm
 
Kryger  M;  Roth  T;  Wang-Weigand  S;  Zhang  J:  The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease.  Sleep Breath 2009; 13:79–84
[CrossRef] | [PubMed]
 
Kryger  M;  Wang-Weigand  S;  Roth  T:  Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea.  Sleep Breath 2007; 11:159–164
[CrossRef] | [PubMed]
 
Krystal  AD;  Richelson  E;  Roth  T:  Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medications.  Sleep Med Rev 2013; 17:263–272
[CrossRef] | [PubMed]
 
Roth  T;  Rogowski  R;  Hull  S;  Schwartz  H;  Koshorek  G;  Corser  B;  Seiden  D;  Lankford  A:  Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.  Sleep 2007; 30:1555–1561
[PubMed]
 
Roth  T;  Rogowski  R;  Hull  S;  Schwartz  H;  Koshorek  G;  Corser  B;  Seiden  D;  Lankford  A:  Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.  Sleep 2007; 30(suppl):1555–1561
[PubMed]
 
Betschart  C;  Hintermann  S;  Behnke  D;  Cotesta  S;  Fendt  M;  Gee  CE;  Jacobson  LH;  Laue  G;  Ofner  S;  Chaudhari  V;  Badiger  S;  Pandit  C;  Wagner  J;  Hoyer  D:  Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.  J Med Chem 2013; 56:7590–7607
[CrossRef] | [PubMed]
 
Hoever  P;  Dorffner  G;  Beneš  H;  Penzel  T;  Danker-Hopfe  H;  Barbanoj  MJ;  Pillar  G;  Saletu  B;  Polo  O;  Kunz  D;  Zeitlhofer  J;  Berg  S;  Partinen  M;  Bassetti  CL;  Högl  B;  Ebrahim  IO;  Holsboer-Trachsler  E;  Bengtsson  H;  Peker  Y;  Hemmeter  UM;  Chiossi  E;  Hajak  G;  Dingemanse  J:  Orexin receptor antagonism, a new sleep-enabling paradigm: A proof-of-concept clinical trial.  Clin Pharmacol Ther 2012; 91:975–985
[CrossRef] | [PubMed]
 
Sun  H;  Kennedy  WP;  Wilbraham  D;  Lewis  N;  Calder  N;  Li  X;  Ma  J;  Yee  KL;  Ermlich  S;  Mangin  E;  Lines  C;  Rosen  L;  Chodakewitz  J;  Murphy  GM:  Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.  Sleep 2013; 36:259–267
[PubMed]
 
Herring  WJ;  Snyder  E;  Budd  K;  Hutzelmann  J;  Snavely  D;  Liu  K;  Lines  C;  Roth  T;  Michelson  D:  Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant.  Neurology 2012; 79:2265–2274
[CrossRef] | [PubMed]
 
Abbott Laboratories. ProSom Prescribing Information. 2006. http://www.drugs.com/pro/prosom.html
 
ECR Pharmaceuticals. ZolpiMist Prescribing Information. 2010. http://www.ecrpharma.com/images/Zolpimist%20Product%20Insert.pdf
 
King Pharmaceuticals Inc. Sonata Prescribing Information. 2006. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM349707.pdf
 
Meda Pharmaceuticals. Edluar Prescribing Information. 2013. http://www.edluar.com/patient/About-EDLUAR/
 
Mylan Pharmaceuticals Inc. Restoril Prescribing Information. 2010. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5416154-8490-4e84-bb6f-4ff0cc605214
 
Purdue Pharma LP. Intermezzo Prescribing Information. 2012. http://app.purduepharma.com/xmlpublishing/pi.aspx?id=i
 
Roxane Laboratories Inc. Halcion Prescribing Information. 2012. http://medlibrary.org/lib/rx/meds/triazolam-11/
 
Sanofi-Aventis. Ambien CR Prescribing Information. 2013. http://products.sanofi.us/ambien_cr/ambiencr.html
 
Sanofi-Aventis. Ambien Prescribing Information. 2013. http://products.sanofi.us/ambien/ambien.html
 
Somaxon Pharmaceuticals I. Silenor Prescribing Information. 2010. http://www.silenor.com/pub/download.ashx?key=%2FwECFA%3D%3D
 
Sunuvion Pharmaceuticals I. Lunesta Prescribing Information. 2012. http://www.lunesta.com/pdf/PostedApprovedLabelingText.pdf
 
Takeda Pharmaceuticals North America. Rozerem Prescribing Information. 2010. http://www.rozerem.com/en/contact_us/
 
West-Ward Pharmaceutical Corp. Dalmane Prescribing Information. 2010. http://medlibrary.org/lib/rx/meds/flurazepam/
 
References Container
+
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Changes in the diagnostic formulation of insomnia in DSM-5 include which of the following:

See Doghramji: Table 1. DSM-5 Criteria for Insomnia Disorder p 6
2.
The risk of insomnia is greatest in which of the following populations:

See Doghramji: Prevalence, p 3
3.
A 75-year old woman requests a psychiatric consultation for frequently interrupted sleep; she falls asleep readily but awakens about six times per night, getting only about 6 hours of sleep between her bedtime of 11 p.m. and rising at 8 a.m. She is apparently in good health but is fatigued and very worried about getting inadequate sleep. A sleep laboratory study revealed no sleep disorder requiring medical management. Which of the following is the first best treatment choice?

See Byrne: Behavioral Strategies of CBT-I, Sleep Restriction Treatment p 35
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 56.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 51.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 13.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 60.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles